Oncoinvent ASA Completes Private Placement and Retail Offering
Oncoinvent ASA has successfully concluded a private placement and a concurrent retail offering, securing capital for its operations. The company announced the completion of a share issue aimed at raising funds.
Oncoinvent ASA has finalized a significant private placement and a concurrent offering to retail investors, a move designed to raise capital for the company's ongoing activities. The company first announced the launch of the share offering on September 22, 2026, detailing the sale of new shares at a fixed price of NOK 90.00 per share.
The primary objective of this capital raise was to strengthen Oncoinvent ASA's financial position, enabling the funding of new research and development initiatives. The company is focused on developing novel cancer therapies, and the raised funds are intended to accelerate the progression of promising treatments into clinical trials.
Specific details regarding the total amount of capital raised and the final number of shares issued are expected to be disclosed shortly. Company statements indicate that the offering was met with considerable interest from both institutional and individual investors, suggesting a positive reception to its business strategy.
Oncoinvent ASA's strategic focus lies in advancing new cancer treatment modalities, particularly those involving radiopharmaceuticals. The company aims to bring to market innovative therapeutic options that offer improved outcomes for cancer patients.